Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Recurrent Cancer" patented technology

Types of Recurrent Cancer. Doctors describe recurrent cancer by where it develops and how far it has spread. The different types of recurrence are: Local recurrence means that the cancer is in the same place as the original cancer or very close to it.

Methods and compositions for treating recurrent cancer

The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
Owner:ABRAXIS BIOSCI LLC

Methods and compositions for treating recurrent cancer

InactiveUS20140017316A1BiocideOrganic active ingredientsRecurrent CancerNab-paclitaxel
The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
Owner:ABRAXIS BIOSCI LLC

Characterizing prostate cancer

The invention relates to identify prostate cancer. The invention provides a method for predicting the recurrence or aggressiveness of prostate cancer, comprising a) determining the Gleason score of a prostate sample, and b) determining the methylation status of a Marker in a biological sample for those patients having a Gleason score of 7 or greater; wherein methylation that exceeds a pre-determined value is indicative of an aggressive or recurrent cancer and methylation that does not exceed such pre-determined value is indicative of indolent cancer. The invention also provides a kit used for predicting the course or aggressiveness of the prostate cancer, which comprising nucleic acid amplification test reagent and a synopsis which instructs the patients having the Gleason score of 7 or greater in the use of the reagent.
Owner:VERIDEX LCC

Antibody-drug conjugates and uses thereof

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 16 mg / kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
Owner:IMMUNOMEDICS INC

Method and compositions for treating cancerous tumors

The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.
Owner:ALLIGER HOWARD

Method and compositions for treating cancerous tumors

The present invention relates to the use of chlorine dioxide compositions for treating cancerous tumors. The present invention relates to compositions and methods for treating cancerous tumors, including naïve, metastatic and recurrent cancers. The compositions comprise chlorine dioxide in an effective amount, which is injected into the cancerous tumor at least once, and often at least several times over the course of treatment. The chlorine dioxide compositions are injected directly into the cancerous tumor and the resulting tumor is effectively eliminated from the patient or subject over a period of one to several days to a few weeks, often after a single injection, or multiple injections at one session into the tumor. Often, an initial injection or multiple injections at one session are sufficient to dissolve the cancerous tumor. Often the cancer is eliminated (as evidenced by no remission) in a period of no more than several days to about two-three months and does not recur.
Owner:ALLIGER HOWARD

Detection of survivin in the biological fluids of cancer patients

The present invention includes a method for diagnosing cancer and predicting recurrent cancer comprising detecting the presence of survivin in the biological fluid of a patient. The present invention also provides kits comprising one or more agents that detect survivin polypeptide or survivin nucleic acid and a container for collecting biological fluid for testing.
Owner:YALE UNIV

Inos-inhibitory compositions and their use as breast cancer therapeutics

Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.
Owner:THE METHODIST HOSPITAL

Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours

The present invention relates to the use of p53 gene therapy to treat recurrent cancers in combination with a radio- or chemotherapy. Patients with recurring cancers are treated with a p53 expression construct followed by subsequent radio- or chemotherapy treatment. Viral and non-viral delivery systems, as well as various radio- and chemotherapy regimens are disclosed.
Owner:INTROGEN THERAPEUTICS INC

Inhibition of granulocyte colony stimulating factor in the treatment of cancer

The present invention relates to the discovery that granulocyte colony stimulating factor (G-CSF) as well as granulocyte colony stimulating factor receptor (G-CSFR) are highly expressed in cancer tissue and the inhibition of G-CSF using a G-CSF inhibitor, which term includes inhibitors of the G-CSF receptor, represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. G-CSF inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
Owner:STC UNM

Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2

The present invention relates to treatment of SCLC with therapeutic ADCs comprising a drug attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody is an hRS7 antibody and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg / kg and 16 mg / kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg / kg, mostly preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the ADC is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan. Preferably, the ADC is administered as a combination therapy with one or more other anti-cancer treatments, such as carboplatin or cisplatinum.
Owner:IMMUNOMEDICS INC

Composition for the Treatment of Resistant Cancers Comprising Oridonin

InactiveUS20100016420A1Improved pharmacokinetic propertiesImprove propertiesBiocideAnimal repellantsTherapy resistantHuman cancer
The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be used in relatively low amounts for the treatment of stage IV or recurrent cancer which may have grown resistant to the traditional chemotherapeutic agents. These compositions comprise oridonin.
Owner:ACTIVEPHYTO TECH LTD

Combination therapies for treating cancer

The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death- 1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
Owner:特沙诺有限公司 +1

Methods of treating cancer and predicting responsiveness to therapy by assessing ZNFX1 exression

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and / or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.
Owner:UNIV OF MARYLAND +3

Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer

The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
Owner:RIGSHOSPITALET +1

Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

The present invention relates to treatment of Trop-2 positive cancers with the combination of anti-Trop-2 ADC and a Rad51 inhibitor. Preferably the drug conjugated to the antibody is SN-38, and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg / kg and 16 mg / kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg / kg. When administered at specified dosages and schedules, the combination of ADC and Rad51 inhibitor can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the combination is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan.
Owner:IMMUNOMEDICS INC

Synergistic compositions consisting essentially of combinations of active agents selected from oridonin, wogonin, and isoliquiritigenin for the prevention of neoplasia

The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be used in relatively low amounts for the treatment of stage IV or recurrent cancer which may have grown resistant to the traditional chemotherapeutic agents. These compositions comprise oridonin.
Owner:ACTIVEPHYTO TECH LTD

Fusion protein comprising CD80 protein and il-2 protein, and composition for preventing or treating cancer comprising t cells expressing chimeric antigen receptors

The present invention relates to: a fusion protein comprising an IL-2 protein and a CD80 protein; and a pharmaceutical composition for preventing or treating a cancer comprising chimeric antigen receptor (CAR)-expressing immune cells. When the fusion protein of the present invention is co-administered with the CAR-expressing immune cells, specifically CAR-T cells, immune activity of the CAR-T cells in tumors is enhanced and sustained. Moreover, when the fusion protein of the present invention is administered alone to a subject with recurrent cancer after the CAR-T cells have been administered, reactivation of the administered CAR-T cells may be induced to kill the recurrent cancer cells. Even when cancer cells are re-transplanted in an animal model in which cancer cells have been completely killed by co-administering the CAR-T cells and the fusion protein of the present invention, the immune activity of the CAR-T cells may be maintained for a long period of time by the fusion protein of the present invention, thereby continuously inhibiting the proliferation of the re-transplanted cancer cells. Accordingly, the fusion protein of the present invention not only enhances and prolongs the immune anticancer activity of the CAR-T cells, but also repeatedly reactivates the administered CAR-T cells, thereby maximizing the efficiency of the CAR-T cells as therapeutic cell resources to ultimately significantly improve the survival rate of patients.
Owner:GI INNOVATION INC

Antibody-drug conjugates and uses thereof

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg / kg and 16 mg / kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
Owner:IMMUNOMEDICS INC

Photo-thermal agent, preparation method thereof and application of photo-thermal agent in treatment of tumors by combining mild photo-thermal therapy with abelsiril

The invention relates to a photo-thermal agent, a preparation method thereof and application of the photo-thermal agent in treating tumors by combining a mild photo-thermal therapy with abesilib. The photo-thermal agent has excellent photo-thermal effect and light stability, and when the photo-thermal agent is used for mild photo-thermal-abelsilib combined treatment, tumor cells are induced to age through abelsilib, then fragile and aged cancer cells are accurately hit by using a mild photo-thermal therapy, and a double-hit effect is formed. According to the therapy, the treatment effect is remarkably improved, meanwhile, side effects are reduced, and the combination therapy has higher targeting property due to the fact that mild photo-thermal energy is low; in addition, treatment is carried out step by step, aging is induced firstly, then photo-thermal treatment is carried out, the scheme can be adjusted according to the reaction of a patient, safety and controllability are improved, and the acute toxicity risk is reduced. According to the invention, drug-induced aging and physical treatment are innovatively combined, and a new treatment approach is provided for refractory or recurrent cancers.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL

Novel interferon variants and bifunctional fusion molecules thereof

The present invention relates to bifunctional fusion molecules comprising a mutated polypeptide ligand (e.g., mutated IFN-α) having reduced biological activity attached to a disease tissue targeting biologic or a tumor associated antigen (TAA)-targeting biologic (e.g., anti-PD-L1 antibody), wherein the targeting biologic or TAA-targeting biologic directs the mutated ligands to cells that express on their surfaces the antigens to which said targeting biologic binds, as well as receptors for said ligands. Importantly, because the mutated polypeptide ligands have reduced biological activity, the resultant fusion molecule have reduced off-target activity / toxicity. More importantly, the targeting of the mutated ligand by the targeting biologic restores the activity of the mutated ligand, with the degree of activity restoration apparently correlated with the level of targeting biologic on the cells. As such, the fusion molecules of the present invention advance the state of art by providing bifunctional fusion molecules having a greater therapeutic window than those previously described. The invention further relates to methods of treating cancer in a patient and in particular, patients with refractory and / or recurrent cancers involving the use of these bifunctional fusion molecules. The invention also relates to methods of treating infectious disease, including but not limited to chronic hepatitis B and C infections in a patient involving the use of these bifunctional fusion molecules.
Owner:REMD BIOTHERAPEUTICS INC

Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease
Owner:MNEMO THERAPEUTICS +2

Use of an antimicrobial peptide TP4 in treating a cancer

ActiveUS10232013B2Peptide/protein ingredientsRecurrent CancerNile tilapia
The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia (Oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (TNBC) with TP4.
Owner:ACAD SINIC

Methods and compositions for treating resistant and recurrent forms of cancer

PendingUS20220088031A1Great therapeutic resistanceFaster prostate cancer recurrenceHydrolasesCytochromesRecurrent CancerPhosphorylation
A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues / biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.
Owner:HEALTH RES INC

Method for determining, predicting and treating cancer

Disclosed herein are methods of detecting or making a risk evaluation of a cancer that has a mutated PREX2 expressed thereon. The cancer may be a primary cancer, a metastatic cancer or a recurrent cancer. According to the embodiment of the present disclosure, the mutation is G258V, S1113R, E1346D or K400fs. Also disclosed herein are methods of treating the subject in need thereof.
Owner:KAOHSIUNG MEDICAL UNIVERSITY

Drugs, uses and methods

The present invention describes a composition for treating refractory cancer and / or recurrent cancer, said composition comprising antibody molecules and agents; and a method of treating refractory cancer and / or recurrent cancer, The methods include administering antibody molecules and agents. Kits comprising the antibody molecules and agents are also described.
Owner:BIOINVENT INT AB

ATAC-array for prediction of disease-free survival in pancreatic cancer

The present disclosure relates to an array-based assay for transposase-accessible chromatin and prognostic molecular markers of treatment-resistant / early recurrent cancer. The present disclosure also relates to predicting an outcome, such as duration of disease-free survival, in a cancer patient.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE +1

Rapid, comprehensive and sensitive method for neoantigen screening from recurrent cancer mutations

A rapid, comprehensive and sensitive method for neoantigen screening from recurrent cancer mutations comprising: (A) STEP 1: selecting recurrent cancer mutations dividing into three tiers based on ranking features; (B) STEP 2: Generating a library of artificial antigen presenting cells (aAPC) co-expressing HLA types (including a list of 13 most frequent HLA class I types covering 66% of Asian population or 67% of Vietnamese population, and a list of 04 most frequent HLA class II types covering 41% Asian population or 50% of Vietnamese population) and a co-stimulatory molecule; and (C) STEP 3: Using the library of aAPC at step (B) for rapid and comprehensive screening for selecting of immunogenic peptides (neoantigens) from the off-the-shelf peptides at step (A) activate T cells via immunological assays (ELISpot or intracellular staining flow cytometry).
Owner:NEXCALIBUR THERAPEUTICS CORP